Hypertension and cardiovascular complications are very common in chronic kidney disease (CKD). Overactivation of sympathetic nervous system is also widely recognized in CKD. Renalase may play an important role in the control of blood pressure (BP) by its regulatory function of catecholamine metabolism. Renalase could be synthesized not only by the kidney but also by cardiomyocytes, liver, and adipose tissue. It probably exerts a hypotensive action, at least in animal models. Whether it metabolizes catecholamines remains to be proved. Another issue that remains to be resolved is the relationship between renalase and renal natriuresis and phosphaturia. In this review, the updated experimental and clinical data on renalase are presented and possible interactions with the endothelium are discussed. Renalase is “a new postulated therapeutic target.” Proof of concept studies are needed to define the pathophysiological link between the kidney, sympathetic tone, BP, and cardiovascular complications.
SantosSFPeixotoAJ. Hypertension in dialysis. Curr Opin Nephrol Hypertens. 2005;14(2):111–118.
2.
ZoccaliCMallamaciFParlongoS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105(11):1354–1359.
3.
SchlaichMPSocratousFHennebryS. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933–939.
4.
XuJLiGWangP. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275–1280.
5.
MalyszkoJMalyszkoJSMikhailidisDPRyszJZorawskiMBanachM. Hypertension and kidney disease: is renalase a new player or an innocent bystander?J Hypertens. 2012;30(3):457–462.
6.
MedvedevAEVeselovskyAVFedchenkoVI. Renalase, a new secretory enzyme responsible for selective degradation of catecholamines: achievements and unsolved problems. Biochemistry (Mosc). 2010;75(8):951–958.
7.
PerticoneFSciacquaAMaioR. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46(3):518–523.
8.
MancusoPAntoniottiPQuarnaJ. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res. 2009;15(1):267–273.
9.
InagamiTNaruseMHooverR. Endothelium as an endocrine organ. Annu Rev Physiol. 1995;57:171–189.
10.
WolinskyH. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res. 1980;47(3):301–311.
11.
LindnerACharraBSherrardDJScribnerBH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290(13):697–701.
12.
MalyszkoJ. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta. 2010;411(19-20):1412–1420.
13.
LiGXuJWangP. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008;117(10):1277–1282.
14.
PandiniVCirielloFTedeschiGRossoniGZanettiGAlivertiA. Synthesis of human renalase 1 in Escherichia coli and its purification as a FAD-containing holoprotein. Protein Expr Purif. 2010;72(2):244–253.
15.
LuftFC. Renalase, a catecholamine-metabolizing hormone from the kidney. Cell Metab. 2005;1(6):358–360.
16.
SalmiMJalkanenS. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science. 1992;257(5075):1407-1409.
17.
MazzoneTChaitAPlutzkyJ. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371(9626):1800-1809.
18.
YuPHWrightSFanEHLunZRGubisne-HarberleD. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta. 2003;1647(1-2):193-199.
19.
MalyszkoJKoc-ZorawskaEMalyszkoJSMysliwiecM.VAP-1, a nover molecule linked to endothelial damage and kidney function in kidney allograft recipients. The Transplant Congress, Berlin; July 15-19, 2012. abstract PO24.088.
20.
LinMSLiHYWeiJN. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem. 2008;41(16-17):1362-1367.
21.
WangFWangNXingTCaoYXiangH. The cloning and expression of renalase and the preparation of its monoclonal antibody. J Shanghai Jiaotong Univ (Sci). 2009;14(13):376–379.
22.
ZbrochEMalyszkoJMalyszkoJSKoc-ZorawsakEMysliwiecM. Renalase, a novel enzyme involved in blood pressure regulation, is related to kidney function but not to blood pressure in hemodialysis patients. Kidney Blood Press Res. 2012;35(6):395–399.
23.
ZbrochEMalyszkoJMalyszkoJKoc-ZorawskaEMysliwiecM.Renalase in peritoneal dialysis patients is not related to blood pressure, but to dialysis vintage. Perit Dial Int. 2012;32(3):348–351.
24.
MalyszkoJZbrochEMalyszkoJSKoc-ZorawskaEMysliwiecM. Renalase, a novel regulator of blood pressure, is predicted by kidney function in renal transplant recipients. Transplant Proc. 2011;43(8):3004–3007.
25.
PrzybylowskiPMalyszkoJKozlowskaSMalyszkoJKoc-ZorawskaEMysliwiecM. Serum renalase, depends on kidney function but not on blood pressure in heart transplant recipients. Transplant Proc. 2011;43(10):3888–3891.
26.
CareyRM. Theodore Cooper lecture: renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension. 2001;38(3):297–302.
27.
ZengCJosePA. Dopamine receptors: important antihypertensive counterbalance against hypertensive factors. Hypertension. 2011;57(1):11–17.
28.
FelderRAJosePA. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol. 2006;2(11):637–650.
29.
WeinmanEJBiswasRSteplockD. Increased renal dopamine and acute renal adaptation to a high-phosphate diet. Am J Physiol Renal Physiol. 2011;300(5):F1123–F1129.
30.
QuinonesHCollazoRMoeOW. The dopamine precursor L-dihydroxyphenylalanine is transported by the amino acid transporters rBAT and LAT2 in renal cortex. Am J Physiol Renal Physiol. 2004;287(1):F74–F80.
31.
PinhoMJSerraoMPSoares-da-SilvaP. High-salt intake and the renal expression of amino acid transporters in spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2007;292(5):F1452–F1463.
32.
KrishnaGGDanovitchGMBeckFWSowersJR. Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med. 1985;105(2):214–218.
33.
SatohTCohenHTKatzAI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest. 1992;89(5):1496–1500.
34.
ZengCSanadaHWatanabeHEisnerGMFelderRAJosePA. Functional genomics of the dopaminergic system in hypertension. Physiol Genomics. 2004;19(3):233–246.
35.
ShikumaRYoshimuraMKambaraS. Dopaminergic modulation of salt sensitivity in patients with essential hypertension. Life Sci. 1986;38(10):915–921.
36.
MorónJABrockingtonAWiseRARochaBAHopeBT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;22(2):389–395.
37.
Sampaio-MaiaBSerrãoPGuimarãesJTVieira-CoelhoMAPestanaM. Renal dopaminergic system activity in the rat remnant kidney. Nephron Exp Nephrol. 2005;99(2):e46–e55.
38.
Sampaio-MaiaBMoreira-RodriguesMPestanaM. Role of chronic inhibition of dopamine-metabolizing enzymes in the regulation of renal sodium and phosphate excretion in the rat remnant kidney. Nephron Physiol. 2006;103(1):14–24.
39.
VermeerCKettelerMShlipakMGWhooleyMAIxJH.The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med. 2010;152(10):640–648.
40.
MirzaMALarssonAMelhusHLindLLarssonTE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207(2):546–551.
41.
HsuHJWuMS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009;337(2):116–122.
42.
GutierrezOMJanuzziJLIsakovaT. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–2552.
43.
MirzaMAAlsioJHammarstedtA. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011;31(1):219–227.
44.
MarsellRMirzaMAMallminH. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2009;20(7):1167–1173.
45.
GutiérrezOMWolfMTaylorEN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011;6(12):2871–2878.
46.
YaoBHarrisRC.ZhangMZ. Intrarenal dopamine attenuates deoxycorticosterone acetate/high salt-induced blood pressure elevation in part through activation of a medullary cyclooxygenase 2 pathway. Hypertension. 2009;54(5):1077–1083.
47.
ZhangMZYaoBWangS. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest. 2011;121(7):2845–2854.
BarakaAEl GhotnyS. Cardioprotective effect of renalase in 5/6 nephrectomized rats [published online May 24, 2012]. J Cardiovasc Pharmacol Ther. 2012.
50.
DesirGVTangLQWangP. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc. 2012;1:e002634.
51.
DesirG. Novel insights into the physiology of renalase and its role in hypertension and heart disease. Pediatr Nephrol. 2012;27(5):719–725.
52.
DesirGV. Role of renalase in the regulation of blood pressure and the renal dopamine system. Curr Opin Nephrol Hypertens. 2011;20(1):31–36.
53.
ZhaoQFanZHeJ. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med. 2007;85(8):877–885.
54.
Farzaneh-FarRDesirGVNaBSchillerNBWhooleyMA. A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: data from the heart and soul study. PLoS One. 2010;5(10):e13496.
55.
GóraJPlachaGSymonidesB. A functional polymorphism in renalase gene (glu37asp) is associated with heart rate, cardiac hypertrophy and urinary noradrenaline in patients with pheochromocytoma. J Hypertens. 2012;30(suppl A):e527–e528.
56.
StecASemczukAFurmagaJKsiazekABuraczynskaM. Polymorphism of the renalase gene in end-stage renal disease patients affected by hypertension [published online May 26, 2011]. Nephrol Dial Transplant. 2011.
57.
BuraczynskaMZukowskiPBuraczynskaKMozulSKsiazekA. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. Neuromolecular Med. 2011;13(4):321–327.
58.
SchlaichMSocratousFEikelisNChopraRLambertGHennebryS. Renalase plasma levels are associated with systolic blood pressure in patients with resistant hypertension. J Hypertens. 2010;28(p):e437.
59.
YanoYHoshideSEtohTTamakiNYokotaNKarioK. Synergistic effect of chronic kidney disease and high circulatory norepinephrine level on stroke risk in Japanese hypertensive patients. Atherosclerosis. 2011;219(1):273–279.
60.
MallamaciFTripepiGMaasRMalatinoLBögerRZoccaliC. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15(2):435–441.
61.
MalyszkoJKoc-ZorawskaEMalyszkoJSKozminskiPZbrochEMysliwiecM. Renalase, stroke and hypertension in hemodialyzed patients. Ren Fail. 2012;34(6):727–731.
62.
ZbrochEMalyszkoJMalyszkoJKoc-ZorawskaEMysliwiecM.Renalase and catecholamines: causative factors or innocent bystanders of hypertension in haemodialysis and peritoneal dialysis patients. ERA-EDTA Congress, Paris; May 24-27, 2012, abstract FP068.
63.
ShawGMorseSAraratMGrahamFL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 2002;16(8):869–871.
64.
AthyrosVGHatzitoliosAIKaragiannisAKaragiannisAMikhailidisDP. Improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. The IMPERATIVE renal analysis. Arch Med Sci. 2011;7(6):984–992.
65.
MalyszkoJZbrochEMalyszkoJMysliwiecMIainaA. The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci. 2010;6(4):539–544.
66.
GlubaAMikhailidisDPLipGYHannamSRyszJBanachM. Metabolic syndrome and renal disease [published online February 2, 2012]. Int J Cardiol. 2012.
67.
Bielecka-DabrowaAAronowWSRyszJBanachM. The rise and fall of hypertension: lessons learned from Eastern Europe. Curr Cardiovasc Risk Rep. 2011;5(2):174–179.
68.
VulicDLoncarSKrnetaM. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. Arch Med Sci. 2010;6(2):270–275.
69.
BarylskiMMalyszkoJRyszJMyśliwiecMBanachM. Lipids, blood pressure, kidney—what was new in 2011?Arch Med Sci. 2011;7(6):1055–1066.
70.
GlubaABanachMHannamSMikhailidisDPSakowiczARyszJ. The role of toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6(4):224–235.
71.
CiceroAFErtekS. Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. Arch Med Sci. 2010;6(4):469–477.
72.
ZbrochEMalyszkoJMalyszkoJKoc-ŻórawskaEMyśliwiecM. Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients. Pol Arch Med Wewn. 2012;122(1-2):40–44.
